Known targets — ChEMBL curated mechanism
CHRM1DRD2DRD3DRD4HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR2APDE3ASIGMAR1
The experimentally established mechanism targets of Lactic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 8/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 8/20 | 0.41 |
| ▸ | APP | P05067 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28572882 | 0.82 | EGFR (0.49) | EGFRAPPCNR2MCL1ALOX5 | |
| Lactic Acid SCHEMBL5072826 | 0.79 | TP53 (0.65) | TP53AKR1C3CYP2C9CYP2C19PTGS2 | |
| Lactic Acid SCHEMBL28184096 | 0.78 | TP53 (0.55) | TP53AKR1C3AKR1C2APPCYP3A4 | |
| Ethane SCHEMBL28414719 | 0.77 | — | — | |
| Formaldehyde SCHEMBL29018323 | 0.74 | — | — | |
| Iodide SCHEMBL28785231 | 0.74 | — | — | |
| Catechol SCHEMBL17999115 | 0.73 | TP53 (0.55) | TP53EGFRCYP3A4CYP2C19PTGS2 | |
| Hydroquinone SCHEMBL27611946 | 0.72 | TP53 (0.61) | TP53CYP3A4ADAMTS4MEN1KMT2A | |
| Lactic Acid SCHEMBL3962098 | 0.71 | TP53 (0.52) | TP53AKR1C3AKR1C2CYP2C9CYP2C19 | |
| SCHEMBL17384107 | 0.71 | ACMSD (0.71) | CYP3A4MCL1PTGS2MEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8505730-B2 | Compositions, kits and regimens for the treatment of skin, especially décolletage | JR CHEM, LLC (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120312717-A1 | COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE | JR CHEM, LLC (US) | 2012-12-13 | — | — | US | disclosed |
| US-8273791-B2 | Compositions, kits and regimens for the treatment of skin, especially décolletage | JR CHEM, LLC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2087880-A2 | Compositions, kits and regimens for the treatment of skin, especially décolletage | Jr Chem, LLC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090176876-A1 | COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE | JR CHEM, LLC (US) | 2009-07-09 | — | — | US | disclosed |
| US-6960347-B2 | Composition based on N-cholesteryloxycarbonyl-4-para-aminophenol and hydroquinone or one of its derivatives | L'OREAL (FR) | 2005-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176876-A1 | COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE | RARG, RARA, RXRG | DRD3 3953/4885TP53 297/4885EGFR 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.